CD274 and lung cancer: Targeted therapies using immune checkpoint inhibitors (ICIs) to block the binding between programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) have achieved good responses in difficult-to-treat malignancies such as lung cancer and melanoma.